These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 31029732

  • 1. Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat.
    Chambers NE, Meadows SM, Taylor A, Sheena E, Lanza K, Conti MM, Bishop C.
    Neuroscience; 2019 Jun 15; 409():180-194. PubMed ID: 31029732
    [Abstract] [Full Text] [Related]

  • 2. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
    Brugnoli A, Pisanò CA, Morari M.
    Neurobiol Dis; 2020 Oct 15; 144():105044. PubMed ID: 32798726
    [Abstract] [Full Text] [Related]

  • 3. Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
    Ztaou S, Maurice N, Camon J, Guiraudie-Capraz G, Kerkerian-Le Goff L, Beurrier C, Liberge M, Amalric M.
    J Neurosci; 2016 Aug 31; 36(35):9161-72. PubMed ID: 27581457
    [Abstract] [Full Text] [Related]

  • 4. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.
    Neuropharmacology; 2014 Feb 31; 77():1-8. PubMed ID: 24067924
    [Abstract] [Full Text] [Related]

  • 5. Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.
    Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C.
    Exp Neurol; 2017 Jun 31; 292():168-178. PubMed ID: 28342749
    [Abstract] [Full Text] [Related]

  • 6. Alterations of M1 and M4 acetylcholine receptors in the genetically dystonic (dtsz) hamster and moderate antidystonic efficacy of M1 and M4 anticholinergics.
    Hamann M, Plank J, Richter F, Bode C, Smiljanic S, Creed M, Nobrega JN, Richter A.
    Neuroscience; 2017 Aug 15; 357():84-98. PubMed ID: 28596119
    [Abstract] [Full Text] [Related]

  • 7. Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia.
    Lanza K, Meadows SM, Chambers NE, Nuss E, Deak MM, Ferré S, Bishop C.
    Neuropharmacology; 2018 Aug 15; 138():304-314. PubMed ID: 29936243
    [Abstract] [Full Text] [Related]

  • 8. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC, Steece-Collier K, Altwal F, Sandoval IM, Kordower JH, Collier TJ, Sortwell CE, West AR, Manfredsson FP.
    J Neurosci; 2020 Apr 29; 40(18):3675-3691. PubMed ID: 32238479
    [Abstract] [Full Text] [Related]

  • 9. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X, Zhao H, Shi H, Wang X, Zhang S, Zhang Z, Zu J, Zhang W, Shen X, Cui G, Hua F.
    Exp Neurol; 2015 Sep 29; 271():168-74. PubMed ID: 26001615
    [Abstract] [Full Text] [Related]

  • 10. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 29; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 11. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
    Iderberg H, McCreary AC, Varney MA, Cenci MA, Newman-Tancredi A.
    Neuropharmacology; 2015 Jun 29; 93():52-67. PubMed ID: 25645393
    [Abstract] [Full Text] [Related]

  • 12. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C, Savoia P, Savoldi D, Barbon A, Missale C.
    Neurobiol Dis; 2013 Jun 29; 54():339-48. PubMed ID: 23328768
    [Abstract] [Full Text] [Related]

  • 13. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L, Robitaille C, Lebel M, Cyr M.
    Neurobiol Dis; 2012 Jan 29; 45(1):645-55. PubMed ID: 22037042
    [Abstract] [Full Text] [Related]

  • 14. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R.
    Biol Psychiatry; 2014 May 01; 75(9):711-22. PubMed ID: 23769604
    [Abstract] [Full Text] [Related]

  • 15. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P, Chalon S, Brotchie JM, Crossman AR.
    Exp Neurol; 2004 Jan 01; 185(1):36-46. PubMed ID: 14697317
    [Abstract] [Full Text] [Related]

  • 16. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X, Zhu Z, Ding X, Wang X, Cui G, Hua F, Xiang J.
    Brain Res; 2018 May 15; 1687():66-73. PubMed ID: 29452071
    [Abstract] [Full Text] [Related]

  • 17. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.
    J Neurochem; 2010 Jul 15; 114(2):499-511. PubMed ID: 20456008
    [Abstract] [Full Text] [Related]

  • 18. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
    Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C.
    J Pharmacol Exp Ther; 2011 Jun 15; 337(3):755-65. PubMed ID: 21402691
    [Abstract] [Full Text] [Related]

  • 19. L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats.
    Huang Y, Shu H, Li L, Zhen T, Zhao J, Zhou X, Luo W.
    ASN Neuro; 2018 Jun 15; 10():1759091418811021. PubMed ID: 30439288
    [Abstract] [Full Text] [Related]

  • 20. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 15; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.